The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

A. Jamnitski, G.M. Bartelds, M.T. Nurmohamed, P.A. van Schouwenburg, D. van Schaardenburg, S.O. Stapel, B.A.C. Dijkmans, L. Aarden, G.J. Wolbink

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)284-288
JournalAnnals of the Rheumatic Diseases
Issue number2
Publication statusPublished - 2011

Cite this